Adaptive Biotechnologies and Collaborators to Present 5 Studies Demonstrating Utility of Immunosequencing to Determine T-cell Function in Chronic and Infectious Diseases at the 2015 American Association of Immunologists Annual Meeting

Data on High-Throughput Pairing of T-cell Receptor Alpha and Beta Sequences to be Presented

News provided by

May 08, 2015, 09:00 ET

SEATTLE, May 8, 2015 /PRNewswire/ -- Adaptive Biotechnologies, the leader in next generation sequencing (NGS) to profile T- and B-cell receptors of the adaptive immune system, and its collaborators will present data demonstrating how profiling a patient's T-cell repertoire may lead to diagnostic and therapeutic discovery in immune-mediated diseases at the American Association of Immunologists (AAI) Annual Meeting in New Orleans from May 8-11, 2015.

"The immunoSEQ™ Platform continues to provide valuable insights on T-cell function," says Dr. Harlan Robins, Chief Scientific Officer and Co-Founder of Adaptive Biotechnologies. "The ability to read and understand T-cell memory puts our immunosequencing technology at the forefront of creating a new diagnostic paradigm for chronic and infectious diseases."

Adaptive is also hosting an exhibitor workshop at AAI on Sunday, May 10, featuring Megan Sykes, MD from Columbia University and Federica Sallusto, PhD from the Institute for Research in Biomedicine, to discuss the advances in immune repertoire profiling using the immunoSEQ Assay.

Representatives from Adaptive Biotechnologies will be exhibiting at AAI (booth #711) to answer questions about its immunosequencing technology.

Oral Presentations:

Abstract #206.40: - High-throughput pairing of T-cell receptor alpha and beta sequences
Presenter: Anna Sherwood, Adaptive Biotechnologies
Time: Saturday, May 9, 2015, 4:30-4:45 p.m.
Location: Room R08

Abstract #134.10: Recombinant human IL7 enhances naive and T stem cell memory reconstitution and enhances repertoire diversity following cytotoxic chemotherapy
Presenter: Hua Zhang, NCI/NIH
Time: 4:45pm-5:00 p.m.
Location: Room R09

Poster presentations:

Abstract #74.01: De novo detection and HLA-association of public T-cell responses to Cytomegalovirus using high-throughput immune repertoire sequencing
Presenter: Ryan Emerson, Adaptive Biotechnologies
Time: Saturday, May 9, 2015, 2:30-3:45 p.m.

Abstract #62.09: Homeostasis and function of Tregs at the site of chronic inflammation
Presenter: Allyson Spence, UCSF
Time: Saturday, May 9, 2015, 2:30-3:45 p.m.

Abstract #148.03: Characterization of cross-reactive T-cell receptors that recognize both Epstein Barr virus and influenza A virus during acute influenza A virus infection
Presenter: InYoung Song, University of Massachusetts Medical School
Time: Sunday, May 10, 2015, 2:30-3:45pm

Abstract #206.40: High-throughput pairing of T-cell receptor alpha and beta sequences
Presenter: Anna Sherwood, Adaptive Biotechnologies
Time: May 11, 2015, 2:30-3:45pm

About Adaptive Biotechnologies

Adaptive Biotechnologies is the pioneer and leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. Adaptive is bringing the accuracy and sensitivity of its immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive also translates immunosequencing discoveries into clinical diagnostics to improve patient care.

About immunoSEQ™

Adaptive helps researchers make discoveries in oncology, autoimmune disorders and infectious diseases by offering fee-for-service access to its proprietary immune profiling sequencing technology under the immunoSEQ™ brand name. The immunoSEQ™ Kit for research use only is now available to facilitate the integration of immunosequencing into research centers. The immunoSEQ™ Assay utilizes high-throughput, bias-controlled sequencing to profile T- and B-cell receptors, enabling in-depth characterization of the adaptive immune response. The immunoSEQ Assay is not for use in diagnostic procedures.

About clonoSEQ™

Adaptive's first clinical application, the two-step clonoSEQ™ Process, enables physicians to utilize sequencing-based minimal residual disease (MRD) detection as a clinical decision-making tool for patients with lymphoid cancers (blood cancers). Clinical validation studies have shown that clonoSEQ™ MRD Test offers significant improvements in sensitivity and performance over other MRD detection methods. clonoSEQ™ Test results are generated in Adaptive's CLIA-certified, CAP-accredited laboratory and provided to the ordering physician in a simple, actionable report via a secure online portal.

The company is also validating a second novel oncology diagnostic to quantify the presence and clonality of Tumor Infiltrating Lymphocytes ("TILs") and to create a reliable measure of "immunocompetency" to predict or monitor response to cancer treatments that directly alter the host immune system.

Logo - http://photos.prnewswire.com/prnh/20120103/SF28632LOGO

SOURCE Adaptive Biotechnologies